Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma

11 Nov 2022

Abstract excerpt

BACKGROUND: Medulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor clinical outcomes and respond poorly to current therapies. Epigenetic deregulation is very common in MYC-driven MB. The bromodomain extra-terminal (BET) proteins and histone deacetylases (HDACs) are epigenetic regulators of MYC transcription and its associated tumorigenic programs. This study aimed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Remodeling and Cancer
Share to Glioma Diagnosis and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36357906
DOI: 10.1186/s13046-022-02530-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) MedulloblastomaPMID 36357906Read ↗

BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cellsSemantic proximity Read ↗

BET Bromodomain Inhibition of <i>MYC</i> -Amplified MedulloblastomaSemantic proximity Read ↗

Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activitySemantic proximity Read ↗

Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent DifferentiationSemantic proximity Read ↗

Epigenetic Dysregulation in MYCN-Amplified NeuroblastomaSemantic proximity Read ↗

Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionSemantic proximity Read ↗

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsSemantic proximity Read ↗

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastomaSemantic proximity Read ↗

MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung CancerSemantic proximity Read ↗

Targeting MYCN-Driven Transcription By BET-Bromodomain InhibitionSemantic proximity Read ↗

PRMT5 as an Epigenetic Target for Group 3 (MYC-driven) MedulloblastomaSemantic proximity Read ↗

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.